Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies

Clinical and Experimental Immunology

Volumn 164, Issue 3, 2011, Pages 357-364

  Borte, M ^a   Bernatowska, E ^b   Ochs, H D ^c   Roifman, C M ^d  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Child Health Institute   (Poland)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Immunoglobulin therapy; Intravenous; Paediatric; Primary immunodeficiency; Subcutaneous

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; BACTERIAL INFECTION; BRAZIL; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; HOME CARE; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFECTION RATE; MALE; NORTH AMERICA; PRIORITY JOURNAL;

BRAZIL; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HOME INFUSION THERAPY; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; INJECTIONS, SUBCUTANEOUS; MALE; NORTH AMERICA;

EID: 79955368148     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04376.x     Document Type: Article

References (22)

1. Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North Am 2008; 28:367-86.
2. Pan-Hammarström Q, Hammarström L. Antibody deficiency diseases. Eur J Immunol 2008; 38:327-33.
3. Gardulf A, Nicolay U, Asensio O etal. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006; 26:177-85.
4. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338:162-6.
5. Gardulf A, Andersen V, Björkander J etal. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365-9.
6. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl M, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94-100.
7. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, IgG S. Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265-73.
8. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin Rev Allergy Immunol 2005; 29:167-72.
9. Berger M, Pinciaro PJ, Flebogamma 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004; 24:389-96.
10. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:413-37.
11. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21:105-16.
12. Tcheurekdjian H, Martin J, Kobayashi R, Wasserman R, Hostoffer R. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states. Allergy Asthma Proc 2006; 27:532-6.
13. Gardulf A, Nicolay U, Asensio O etal. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-42.
14. Nicolay U, Kiessling P, Berger M etal. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:65-72.
15. Gardulf A, Borte M, Ochs HD, Nicolay U, Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126:81-8.
16. Schauer U, Stemberg F, Rieger CH etal. IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem 2003; 49:1924-9.
17. Ochs HD, Pinciaro PJ, Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in patients with primary immunodeficiency diseases. J Clin Immunol 2004; 24:309-14.
18. Eijkhout HW, van Der Meer JW, Kallenberg CG etal. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001; 135:165-74.
19. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98:1127-31.
20. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998; 79:48-51.
21. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96:1474-8.
22. Gardulf A, Björvell H, Andersen V etal. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21:917-27.